Effect of Extended-Release Oxymorphone Hydrochloride (Opana ER), Taken Fasting Versus With Food, on Cognitive Functioning in Opioid-Tolerant Subjects: a Randomized, Single-Blinded, Cross-Over Study.

Trial Profile

Effect of Extended-Release Oxymorphone Hydrochloride (Opana ER), Taken Fasting Versus With Food, on Cognitive Functioning in Opioid-Tolerant Subjects: a Randomized, Single-Blinded, Cross-Over Study.

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Sep 2011

At a glance

  • Drugs Oxymorphone (Primary)
  • Indications Pain
  • Focus Adverse reactions
  • Most Recent Events

    • 29 Aug 2010 Primary endpoint 'Cambridge Neuropsychological Test Automated Battery - Rapid Visual Information Processing Test score' met, according to an abstract presented at the 13th World Congress on Pain.
    • 29 Aug 2010 Results presented in an abstract at the 13th World Congress on Pain.
    • 29 Aug 2010 Status changed from recruiting to completed, based on an abstract presented at the 13th World Congress on Pain.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top